US Bancorp DE Increases Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

US Bancorp DE increased its position in Acelyrin, Inc. (NASDAQ:SLRN) by 77.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,854 shares of the company’s stock after buying an additional 7,336 shares during the quarter. US Bancorp DE’s holdings in Acelyrin were worth $83,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of SLRN. Russell Investments Group Ltd. bought a new stake in shares of Acelyrin in the 1st quarter worth approximately $183,000. ProShare Advisors LLC raised its position in Acelyrin by 69.9% in the 1st quarter. ProShare Advisors LLC now owns 19,871 shares of the company’s stock worth $134,000 after purchasing an additional 8,176 shares during the period. Blair William & Co. IL bought a new stake in Acelyrin in the first quarter worth $936,000. Vanguard Group Inc. boosted its position in Acelyrin by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock valued at $42,103,000 after buying an additional 81,633 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its position in Acelyrin by 118.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after purchasing an additional 3,921 shares during the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Acelyrin Stock Performance

Shares of NASDAQ:SLRN opened at $4.69 on Friday. Acelyrin, Inc. has a 52-week low of $3.36 and a 52-week high of $9.20. The firm has a market capitalization of $468.11 million, a P/E ratio of -1.91 and a beta of 1.98. The stock has a 50 day moving average price of $5.41 and a 200-day moving average price of $5.02.

Wall Street Analyst Weigh In

SLRN has been the subject of a number of analyst reports. Piper Sandler dropped their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Morgan Stanley dropped their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, August 19th. HC Wainwright boosted their target price on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Wells Fargo & Company raised their price target on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.